“The performance of financial markets since the end of May has added to the uncertainty whether enough proceeds are achievable that reflect the value of Evonik,” the RAG Foundation said yesterday. “The certainty of a flotation based on an appropriate valuation of Evonik is a prerequisite of the IPO.”
RAG owns 75 per cent of Evonik while private equity firm CVC owns 25 per cent.
Sources close to the matter have said Evonik is looking to raise as much as €5bn (£4.04bn).
RAG said in April last year it was preparing for an IPO of Evonik, but put the plans on ice in September due to weak markets.
Sources close have said Evonik’s owners hope the IPO will value the chemicals group at around €15bn.
According to two people on RAG’s board, investors are not willing to pay anything close to that and are rather looking at a valuation of around €12bn. One banking source said that the threat to pull the IPO is all part of a strategy designed to achieve the fuller valuation. Another meeting of RAG’s board is planned for 18 June.
Deutsche Bank and Goldman Sachs are joint global coordinators and joint bookrunners for the offering. BofA Merrill Lynch, Credit Suisse and JP Morgan are additional bookrunners.